BioWorld

May 19, 2004

Celltech Agrees To Buyout By UCB For $2.7B In Cash

LONDON - Celltech Group plc, the UK's largest biotechnology company, has agreed to be taken over by UCB SA, of Brussels, Belgium, in an all-cash deal that values Celltech at about £1.5 billion (US$2.7 billion). (BioWorld Today) Read More

Chiron's Failed Sepsis Drug Taking On CAP In Phase III

FDA: Critical Path Initiative' Sharpens Drug Development

Pozen Starts Phase III Migraine Program, Hits $15M Milestone

Neose Offering Brings In $34M For EPO, G-CSF Development

Panacos Attracts $18.3M Round To Fund HIV Drug Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 10, 2025.

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...